Form 4: NewAmsterdam Pharma Co N.V. Executive Louise Kooij Acquires 15,000 Restricted Stock Units

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reports the acquisition of 15,000 restricted stock units.

Summary

• On January 7, 2025, Louise Frederika Kooij, the Chief Accounting Officer of NewAmsterdam Pharma Co N.V., acquired 15,000 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one ordinary share of NewAmsterdam Pharma Co N.V.
• The RSUs were granted for no consideration.
• The RSUs vest in three equal installments, with 1/3 vesting on each of the first, second, and third anniversaries of the vesting start date, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units granted to an executive. The vesting schedule suggests a long-term commitment, which is mildly positive.

Positives

• The acquisition of RSUs by a key executive may signal confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the reporting person's continued service, incentivizing long-term commitment to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of securities by an officer of NewAmsterdam Pharma.

Stakeholder Impact

• The RSU grant aligns the executive's interests with those of the shareholders, incentivizing actions that increase shareholder value.

Key Dates